Affiliated to Shenzhen Salubris Pharmaceuticals Limited by Share Ltd., it has focused on research and development of biotechnology innovative drugs and established three novel medicine R&D platforms of recombinant protein drugs, antibody drugs and gene therapy drugs by possessing a complete and innovative drug development chain from new molecular design, process development, quality research and clinical research to industrialization.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Limited by Share Ltd. and located in MD, USA, it has performed studies of novel biopharmaceutics with global independent intellectual property rights by a group of leading new drug experts devoting themselves to the early R&D of innovative drugs, and achieved synchronous declaration in China and the United States, thereby effectively enhancing our international competitiveness in R&D of innovative drugs.
More
Wholly-owned by Shenzhen Salubris Pharmaceuticals Co., Ltd., it has been mainly engaged in the research, development, production and sales of Biologics, and established Suzhou Engineering Technology Research Center for Recombinant Protein Medicine including recombinant proteins, monoclonal antibodies and so on involved in fields of osteoporosis, anti-tumor, diabetes, heart diseases and other diseases. The production platform established in accordance with the requirements of Chinese GMP and EU GMP standards has prokaryotic production lines and eukaryotic production lines. The eukaryotic production lines are the most advanced intelligent 2000L Flexfactory production platform in China, which can be used for clinical production and commercial production of extracellular expression products such as CHO cells.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd., it is committed to research, development and production of APIs for cardiovascular and cerebrovascular diseases, diabetes, anti-tumor, osteoporosis, anti-infection and others. The production lines are established in accordance with Chinese GMP and EU GMP standards and obtain EU CEP certificate.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd., it has been mainly engaged in the research, development, production and sales of cephalosporin APIs, chemical APIs, pharmaceutical intermediates and enzyme products.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd., it has focused on research, development, production and sales of high-end intervention medical device, and involved in cardio-cerebrovascular, peripheral vascular and other market segments.
More
As a holding subsidiary of Shenzhen Salubris Biomedical Engineering Co., Ltd., it has produced innovative medical device products with independent intellectual property rights, and committed to research, development and commercialization of products in fields such as structural heart disease and peripheral vascular diseases.
More
Wholly-owned by Shenzhen Salubris Medtech Co., Ltd., it has been committed to research, development and commercialization of innovative medical devices in nerve intervention and peripheral vascular intervention. The developed world's first Maurora® rapamycin drug-eluting vertebral artery stent is the special drug eluting stent for vertebral artery that was approved by NMPA and commercialized in China.
More
Wholly-owned by Shenzhen Salubris Medtech Co., Ltd., it has drug-loaded coating technology platform with independent intellectual property rights and achieves technological breakthroughs in multiple sub-fields based on research, development, production and sales of cardiac intervention medical devices.
More
Affiliated to Shenzhen Salubris Pharmaceuticals Co., Ltd. and located in Hong Kong, China, it has been mainly engaged in trade and technical support services.
More
